New insulin biosimilar faces off against market leader in early trial
NCT ID NCT07364669
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 1 trial tested whether a new biosimilar insulin called Insulex® R works similarly to the standard Humulin® R. Forty healthy adults received a single injection of each insulin in a crossover design. Researchers measured how the body absorbed the insulin and how it affected blood sugar levels. The goal was to see if the two insulins are comparable, which could offer more options for diabetes treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Insulex® R (biosimilar human insulin)
What this could lead to
If successful, this could show that Insulex® R is a safe and effective alternative to Humulin® R for managing diabetes.
What could go wrong
This is an early Phase 1 study in healthy people, not those with diabetes. It only checks short-term effects, so it may not predict real-world outcomes or long-term safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Prosciento, Inc
San Diego, California, 92121, United States